Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …

Pancreatic cancer is the fourth leading cause of cancer-related death among men and
women in the United States. A major challenge in treatment remains patients' advanced …

Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …

Purpose: KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal
adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to …

Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …

Background In a phase 1–2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus
gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic …

Chemotherapy is an important part of multimodality pancreatic cancer treatment. After
curative resection, adjuvant chemotherapy can significantly improve disease free survival …